Akita Biosciences
Akita Biosciences is redefining health with innovative, science-backed nasal sprays designed for prevention, precision, and everyday wellness. The company develops nasal sprays that combine world-class science and innovative formulations to enhance health, targeting the nasal passages where airborne germs, allergens, and irritants first enter the body. Backed by groundbreaking research from Harvard Medical scientists, Akita aims to set new standards in respiratory health and preventive health, leveraging advanced nasal spray platforms to optimize delivery, absorption, and effectiveness. The company's mission is to help people stay ahead of airborne threats and improve overall health through cutting-edge nasal science.
Industries
Nr. of Employees
small (1-50)
Akita Biosciences
Boston, Massachusetts, United States, North America
Products
Drug-free nasal hygiene spray
Over-the-counter nasal spray formulated to create a 3D cleansing matrix in the nasal passages that forms a long‑lasting protective gel-like coating to support nasal hygiene and reduce exposure to airborne contaminants.
Drug-free nasal hygiene spray
Over-the-counter nasal spray formulated to create a 3D cleansing matrix in the nasal passages that forms a long‑lasting protective gel-like coating to support nasal hygiene and reduce exposure to airborne contaminants.
Services
Partnership collaboration for research and commercialization
Collaborative engagements with academic labs, retailers, and commercial parties to develop, evaluate, and commercialize nasal health products.
Partnership collaboration for research and commercialization
Collaborative engagements with academic labs, retailers, and commercial parties to develop, evaluate, and commercialize nasal health products.
Expertise Areas
- Nasal drug delivery and formulation
- Mucoadhesive biomaterial design
- Preclinical efficacy testing and animal challenge models
- Macromolecule (biologic) nasal delivery
Key Technologies
- Nasal mucosal delivery
- Mucoadhesive gel barrier formulations
- Pathogen capture and neutralization formulations
- Macromolecule encapsulation (up to ~150 kDa)